ZYME (Zymeworks) Moat Score: 5/10 (As of Jul. 03, 2026)


ZYME Zymeworks Inc ZYME
66 GF Score
Price $26.31
GF Value $24.08
Valuation Fairly Valued
! 5 Warning Signs
View Full Analysis

What is Zymeworks Moat Score?

Zymeworks ZYME +2.47% 66 Moat Score is 5 as of Jul. 03, 2026. GuruFocus rates ZYME with a GF Score™ of 66/100 and a GF Value™ of $24.08 (Fairly Valued). The stock has 5 warning signs investors should review. Among 1,399 Biotechnology companies, Zymeworks ranks better than 96.71% on this metric.

Zymeworks has the Moat Score of 5, which implies that the company might have Narrow Moat - Solid narrow moat.

Zymeworks has Narrow Moat: Zymeworks Inc has a solid narrow moat based on its valuable intellectual property and R&D capabilities in the biotech sector. While it has some regulatory protection, it lacks strong brand strength and customer loyalty. The competitive landscape limits its pricing power and market share.

Moat Score is a ranking system developed by GuruFocus to assess a company's ability to sustain a competitive advantage, rated on a scale from 0 to 10. It takes into account key factors such as market leadership, cost advantages, network effects, customer switching costs, and more.

The company's Moat Score is based on these criteria:

1. Market leadership and sustainable market share
2. Network effects and significant customer switching costs
3. Valuable intellectual property and patents
4. Strong brand strength and deep customer loyalty
5. Durable cost advantages (e.g., economies of scale, proprietary technology)
6. Significant regulatory barriers and exclusive licenses
7. Superior distribution network
8. Strong and sustainable pricing power
9. Consistent and impactful innovation and R&D capabilities

Based on the research, GuruFocus believes Zymeworks might have Narrow Moat - Solid narrow moat.

Zymeworks  (NAS:ZYME) Moat Score Explanation

The Moat Score ranges from 0 to 10, with 10 as the highest. GuruFocus divided Moat Score into following 8 categories:

Moat Score Moat Level
10Wide Moat - Exceptionally dominant and durable wide moat
8 - 9Wide Moat - Clear and robust wide moat
7Wide Moat - Entry-level wide moat, clearly possessing durable advantages
6Narrow Moat - Strong narrow moat, clearly distinguishable but not wide
5Narrow Moat - Solid narrow moat
4Narrow Moat - Discernible but modest moat
1 - 3No Moat - Very weak/transient advantages
0No Moat - No discernible moat

Zymeworks Moat Score Related Terms

ZYME vs SRPT, BCAX, INVA: Moat Score Comparison

For the Biotechnology subindustry, Zymeworks's Moat Score, along with its competitors' market caps and Moat Score data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Zymeworks Moat Score vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Zymeworks's Moat Score distribution charts can be found below:

* The bar in red indicates where Zymeworks's Moat Score falls into.


ZYME
66GF Score
Zymeworks Inc ZYME
Moat Score is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis
Frequently Asked Questions Learn more about Moat Score →
What does a Moat Score of 5 mean?
Zymeworks (ZYME) has a Moat Score of 5 as of Jul. 03, 2026. Moat Score is a ranking system developed by GuruFocus to assess a company's ability to sustain a competitive advantage, rated on a scale from 0 to 10. It takes into account key factors such as market leadership, cost advantages, network effects, customer switching costs, and more. According to the industry distribution chart, Zymeworks ranks #46 out of 1399 companies in the Biotechnology industry, placing it in the top 3.3%.
Is Zymeworks' Moat Score too high?
Zymeworks' current Moat Score is 5. The Biotechnology industry median Moat Score is 2.00. Zymeworks' value of 5 is 150% above this industry median. Based on the distribution chart, Zymeworks ranks #46 out of 1399 companies in the Biotechnology industry, which is in the top quartile — a strong position relative to peers. Overall, Zymeworks has a GF Score™ of 66/100 and is considered Fairly Valued, reflecting its overall financial health beyond just this single metric.
How does Zymeworks' Moat Score compare to SRPT and BCAX?
According to the Biotechnology industry distribution chart, Zymeworks ranks #46 out of 1399 companies for Moat Score. This places Zymeworks in the top 3% of its industry — outperforming the majority of peers. The industry median Moat Score is 2.00. Zymeworks' value of 5 is 150% above this benchmark. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Moat Score for a Biotechnology company?
The median Moat Score among Biotechnology companies is 2.00, based on 1,399 companies in the industry. Companies in the top quartile (top 25%) have a Moat Score significantly above this median, while those in the bottom quartile fall well below. However, Moat Score should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Zymeworks's current Moat Score of 5 is 150% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Moat Score mean?
A high Moat Score can signal that a stock is expensive relative to its fundamentals. Moat Score is a ranking system developed by GuruFocus to assess a company's ability to sustain a competitive advantage, rated on a scale from 0 to 10. It takes into account key factors such as market leadership, cost advantages, network effects, customer switching costs, and more. For the Biotechnology industry, the median Moat Score is 2.00 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Zymeworks's current Moat Score is 5. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Zymeworks stock overvalued right now?
Based on GuruFocus' analysis, Zymeworks (ZYME) is currently considered Fairly Valued. The stock's GF Value™ is $24.08, compared to a current price of $26.31 — trading 9.3% above its estimated fair value. The current Moat Score is 5 and 150% above the Biotechnology industry median of 2.00. Zymeworks' overall GF Score™ is 66/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Moat Score calculated?
Moat Score is calculated from a company's financial statements. For Zymeworks (ZYME), the current Moat Score is 5 as of Jul. 03, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Zymeworks (ZYME) Overvalued in 2026?

Based on GuruFocus' analysis, Zymeworks stock appears to be overvalued. The current stock price of $26.31 is trading 9.3% above its estimated GF Value™ of $24.08. GuruFocus considers Zymeworks to be Fairly Valued.

Key valuation signals for ZYME:

  • Moat Score: 5
  • GF Value™: $24.08 vs. price of $26.31 (9.3% above fair value)
  • GF Score™: 66/100 with 5 warning signs
  • Industry Position: 150% above the Biotechnology median (#46 of 1399)

No single metric tells the full story. See the ZYME stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Zymeworks Business Description

Other Exchanges ZA8:Germany
Address 108 Patriot Drive, Suite A, Middletown, DE, USA, 19709
Zymeworks Inc is a clinical-stage biopharmaceutical company dedicated to the discovery, development and commercialization of next-generation multifunctional biotherapeutics. Its suite of therapeutic platforms and its fully integrated drug development engine enables precise engineering of differentiated therapeutic product candidates. Its clinical candidate, zanidatamab, is a novel HER2-targeted bispecific antibody currently being evaluated in multiple Phase 1, Phase 2, and pivotal clinical trials globally as a targeted treatment option for patients with solid tumors that express HER2. It is also advancing a deep preclinical pipeline in oncology and other therapeutic areas.
66GF Score

Get the complete analysis for ZYME

Moat Score is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$26.31
Price
$24.08
GF Value